Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2017-12-01 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding the company's use of idle raised funds for cash management, detailing purchases and redemptions of financial products. It includes specific dates, amounts, and product types but does not contain comprehensive financial statements or detailed financial analysis. The document length is short (1901 characters) and it is an announcement of ongoing financial management activities rather than a full financial report. It fits the category of Capital/Financing Update (CAP) as it updates on the company's financing activities related to raised funds management.
2017-12-01 Chinese
独立董事关于公司第二届董事会第十七次会议相关事项的独立意见
Regulatory Filings
2017-11-30 Chinese
关于调整境外投资暨关联交易公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding an adjustment in overseas investment and related party transactions involving the company, its controlling shareholder, and an associated party. It includes descriptions of agreements, financial data of related parties, board approvals, independent opinions, and implementation status. The content focuses on disclosure of a specific related party transaction and investment adjustment rather than presenting financial statements or audit results. It does not contain comprehensive financial reports or earnings data. The document is a formal announcement of a corporate transaction and related party dealings, fitting the category of Regulatory Filings (RNS) as it does not match other more specific categories like Annual Report, Interim Report, or Capital/Financing Update. The length and detail confirm it is not a brief notice or a report publication announcement but a substantive regulatory disclosure.
2017-11-29 Chinese
使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding the progress of cash management using idle raised funds. It details contracts signed with banks for purchasing wealth management products, amounts invested, returns, and current balances. The document is relatively short (1860 characters) and focuses on updates about the company's use of idle raised funds for financial products. It does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or interim report, nor an earnings release. It is a specific update on capital management activities related to fundraising proceeds. Therefore, it fits best under Capital/Financing Update (CAP).
2017-11-01 Chinese
使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of cash management using idle funds. It details contracts signed with banks for purchasing financial products, amounts invested, returns, and current balances. The document is relatively short (2121 characters) and focuses on updates about financing activities related to cash management and investment products. There is no indication of it being a full financial report, audit, or earnings release. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The content fits best under Capital/Financing Update (CAP) as it provides updates on the company's financing activities and capital management.
2017-11-01 Chinese
关于取得医疗器械注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of medical device registration certificates from a regulatory authority (Henan Food and Drug Administration). It details the product registration numbers, intended uses, and impact on company performance. There is no financial data, no mention of financial results, no meeting materials, no voting results, no executive changes, no legal proceedings, no capital changes, and no earnings information. The document is a regulatory announcement about product certification, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2017-10-30 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.